Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the target of a significant decline in short interest in the month of May. As of May 15th, there was short interest totalling 1,970,000 shares, a decline of 16.9% from the April 30th total of 2,370,000 shares. Based on an average trading volume of 2,520,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 4.1% of the shares of the company are short sold.
Wall Street Analyst Weigh In
Several analysts have issued reports on MIST shares. Cowen downgraded shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. HC Wainwright started coverage on shares of Milestone Pharmaceuticals in a research report on Thursday. They set a "buy" rating and a $5.00 price target for the company. TD Securities downgraded shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Finally, TD Cowen downgraded shares of Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $7.00.
View Our Latest Research Report on MIST
Milestone Pharmaceuticals Stock Up 5.2%
Shares of MIST traded up $0.09 during midday trading on Thursday, hitting $1.74. The company had a trading volume of 511,287 shares, compared to its average volume of 912,629. The company's 50 day moving average price is $1.14 and its 200 day moving average price is $1.69. The stock has a market cap of $92.84 million, a price-to-earnings ratio of -2.14 and a beta of 0.92. Milestone Pharmaceuticals has a 52 week low of $0.63 and a 52 week high of $2.75. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18.
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.12). On average, equities research analysts predict that Milestone Pharmaceuticals will post -0.62 EPS for the current year.
Institutional Trading of Milestone Pharmaceuticals
A number of institutional investors have recently made changes to their positions in MIST. Toronto Dominion Bank bought a new stake in shares of Milestone Pharmaceuticals in the 4th quarter worth approximately $1,770,000. Northern Trust Corp raised its holdings in shares of Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock valued at $137,000 after acquiring an additional 30,772 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $73,000. Jones Financial Companies Lllp raised its holdings in shares of Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock valued at $26,000 after acquiring an additional 10,000 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $729,000. 86.18% of the stock is owned by institutional investors and hedge funds.
About Milestone Pharmaceuticals
(
Get Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Further Reading
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.